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REVIEW
Abstract: COPD is uniquely situated as a chronic disease at the beginning of the 21st century;
it is not only an established major cause of mortality and morbidity but is increasing in
prevalence despite current medical interventions. In addition COPD is not a stable disease
but its natural history is punctuated by periods of acute deterioration or exacerbations.
Exacerbations generate considerable additional morbidity and mortality, and directly affect
patients’ quality of life. However, despite significant advances in understanding and treating
this disease, exacerbations continue to be the major cause of COPD-associated hospitalization,
and provision for their management incurs considerable health care costs. This review will
consider the current management of COPD exacerbations and how new clinical strategies
may improve outcome of these important clinical events.
Keywords: COPD, exacerbation therapy
Introduction
There can be little doubt that COPD is currently one of the most important chronic
diseases worldwide. Whether the burden of disease is measured by mortality, estimates
of morbidity, or associated health care burden and costs, it is consistently ranked at
or near the top in the hierarchy of global diseases (Murray and Lopez 1996). However,
unlike other diseases of comparable importance both its prevalence and consequent
health care burden are increasing (Murray and Lopez 1996). Furthermore the
emergence of COPD as a significant disease outside its established focus in the
industrialized nations suggests growth in the international impact of this disease will
continue (WHO 2000).
The natural history of COPD is of progressive deterioration in lung function as a
result of persisting lung inflammation in response to inhaled pollutants, chiefly tobacco
smoke (Pauwels et al 2001). This process results in the eventual development of
chronic symptoms which may eventually become disabling (Celli et al 2004). The
course of the disease is punctuated by episodes of acute deterioration in symptoms
termed exacerbations. COPD exacerbations are associated with heightened levels of
airway and systemic inflammation (Bhowmik et al 2000; Wedzicha et al 2000) and
consequently contribute to disease progression (Kanner et al 2001; Donaldson et al
2002), and have prolonged effects on functional ability (Donaldson et al 2005) and
health status (Seemungal et al 1998). There is currently no universally accepted
definition of exacerbation, which may in part be due to the heterogeneity of these
events but also due to the lack of an objective diagnostic measure or “gold standard”
for the symptom-based diagnostic criteria that are in common usage (Seemungal et
al 1998; Celli et al 2004). The median annual frequency of exacerbations using a
symptom based diagnostic system is between two and three (Seemungal et al 1998);
however, certain individuals suffer a greater number of exacerbations per year. These
frequent exacerbators are at particular risk of the adverse consequences of
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exacerbations, with faster decline in FEV1 (Donaldson
et al 2002), worse health status (Seemungal et al 1998),
and greater risk of hospitalization (Garcia-Aymerich et
al 2001) than their counterparts with infrequent
exacerbations.
The etiology of exacerbations is complex, with a number
of environmental agents identified as playing a role in their
genesis. The most commonly detected trigger for
exacerbations is airway infection, and a role for respiratory
viral (Seemungal et al 2000b, 2001; Rohde et al 2003) and
bacterial (Sethi et al 2000; White et al 2003) infection has
been shown not only in initiating but also in modulating the
severity of these events. However, not all exacerbations are
associated with an identifiable pathogen, and a role for
environmental pollution (Yang et al 2005) and changes in
temperature (Koskela et al 1996) have been suggested.
Considering the spectrum of disease and the array of
etiologies that may trigger exacerbations or modulate their
natural history, it is no surprise that there is marked
heterogeneity both in the clinical severity and time course
of these events (Seemungal et al 2000a). Hence, predicting
responses to prescribed therapy can be difficult. Whilst
current pharmacological therapies target the inflammation,
infection and bronchoconstriction associated with
exacerbations, their efficacy even in combination is limited,
and targeting therapies to presumed etiologies of particular
exacerbations remains largely a matter of clinical judgment.
Furthermore, the prescription of pharmacological treatments
alone does not address the deleterious effects on functional
performance, and psychological and social factors caused
by exacerbation.
Predicting outcome of exacerbations is therefore
problematic; however, patients with more severe disease at
baseline are less likely to do well (Garcia-Aymerich 2001;
Wouters 2004), particularly those with poor baseline
functional capacity (Garcia-Aymerich et al 2003). Indeed,
following severe, hypercapnic, exacerbations requiring
hospital admission, over a third of patients may require
mechanical ventilation, with in-hospital mortality more than
10% (Connors et al 2004). Furthermore, the outcomes
following admission remain poor, with 80% of patients
requiring inpatient management of a severe exacerbation
re-admitted within a year (Chu et al 2004). The outcome of
less severe exacerbations managed in primary care is less
well described. However, observational studies have
revealed that a significant proportion of patients
experiencing exacerbation symptoms fail to recover back
to baseline levels (Seemungal et al 2000a) and that poor
outcomes are often related to failure to seek appropriate
therapy (Wilkinson et al 2004).
Despite recognition of the poor prognosis associated
with COPD exacerbations requiring hospitalization and
attempts to summarise the evidence base in management
guidelines there are indications that appropriate standards
of care for acute exacerbations are not met and simple
assessments to identify at risk patients not completed
(Roberts et al 2001). There is obviously considerable
scope to improve management of COPD exacerbations,
and thus to improve outcomes. This article will review
potential strategies that may improve delivery of currently
available therapies and hence improve exacerbation
outcomes, whilst the pursuit of novel more efficacious
pharmacotherapy continues.
Prevention is better than cure
 Prevention of exacerbations will have obvious benefits for
patients and health care providers alike. There are a number
of interventions that have been shown to reduce the
incidence of exacerbations; however, their use is currently
far from systematic (Johnson and Stevenson 2002). It is of
course difficult to target potentially effective preventive
therapies if the appropriate diagnosis of COPD is not initially
established. The findings of the confronting COPD study
show that under-diagnosis of COPD and lack of public
awareness of the disease remain significant problems which
may impact on outcomes of the disease (Rennard et al 2002).
Improving diagnosis rates particularly with the provision
of access to spirometry in primary care is fundamental to
the appropriate provision of preventive therapy.
Tobacco smoking is the key etiological factor in the
development of COPD and smoking cessation therefore
should be central to any management strategy for the
condition. Smoking cessation has established beneficial
effects on the rate of decline in lung function (Fletcher and
Peto 1997), chronic symptoms (Willemse et al 2004), and
the development of co-morbidities. In addition, beneficial
effects of stopping smoking on exacerbation frequency have
been described (Kanner et al 2001), and furthermore the
impacts of exacerbations in terms of FEV1 decline (Kanner
et al 2001) and hospitalization (Gotfredsen et al 2002) are
ameliorated and response to therapy improved (Chang et al
1995; Burge et al 2003). The importance of smoking
cessation early in the disease state is highlighted by the
observation that the impact of exacerbations on FEV1 decline
is apparent in smokers but not ex-smokers in mild disease
(Kanner et al 2001), but the beneficial effect of smokingInternational Journal of COPD 2006:1(3) 337
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cessation on this effect of exacerbations is no longer apparent
in patients with more established airway obstruction
(Donaldson et al 2002).
Respiratory infections are important triggers to
exacerbations and hence are an appropriate target for
preventive therapy. Influenza vaccination has been shown
to reduce the need for out-patient and in-patient care and to
benefit mortality in elderly patients with lung disease (Nichol
et al 1999). The evidence that pneumococcal vaccination is
of similar benefit in this patient group is lacking; however,
influenza and pneumococcal vaccination are widely
recommended to all patients with established COPD, and
improving compliance is an important target in primary care.
There is now an evidence base suggesting that although
inhaled corticosteroid therapy does not impact on the rate
of lung function decline, it may have beneficial effects on
exacerbation frequency and decline in health status (Burge
et al 2000). The beneficial effects of inhaled corticosteroids
when used in combination with long acting β2-agonists are
more pronounced (Calverley et al 2003). Inhaled long-acting
anti-cholinergics have also been shown to have beneficial
effects on exacerbation frequency and hospitalization for
exacerbations, with effects more pronounced with greater
severity of disease (Niewohner et al 2005).
Recent guidelines have tried to simplify the algorithms
for prescription of these medications (Celli et al 2004; NICE
2004), but the data and therefore guidance are lacking on
whether the beneficial effects of inhaled therapy are additive
if multiple therapies of different classes are used.
Furthermore, prescription practice remains primarily
focused on controlling stable symptoms rather than
preventing or modulating the severity of exacerbations.
Particularly in patients with a history of frequent
exacerbations, the prescriber should not ignore the goal of
preventing exacerbations, as well as managing day-to-day
symptoms.
Issues of poor compliance with inhaled medication have
not been fully addressed in COPD, nor have potential
difficulties with use of inhaler devices. Improving
compliance with inhaled therapy can have tangible benefits
for patients and practitioners alike (Worth and Dhein 2004);
however, understanding of this problem, particularly in a
population of elderly patients with COPD and significant
co-morbidities, is incomplete.
Use of oral therapies, particularly mucolytic agents,
currently varies greatly from country to country. The
evidence for their efficacy in preventing exacerbations has
been until recently based upon a number of smaller studies.
However a meta-analysis (Cochrane review) demonstrated
that a significant reduction in exacerbation frequency could
be gained by regular use of mucolytics such as N-acetyl
cysteine (Poole and Black 2001). However, the mechanism
of action, whether mucolytic or antioxidant, remains
uncertain. These findings are somewhat at odds with the
recent results of the BRONCUS study. This large multi-
centred study of the effects of NAC over 3 years failed to
show an overall benefit on exacerbation frequency.
However, a sub-group analysis suggested a benefit in
patients not receiving inhaled corticosteroids (Decramer et
al 2005). Use of long-term oral corticosteroids has been
associated with adverse outcomes with high levels of
systemic side-effects; therefore long-term use is not
recommended (Walters et al 2005). The role of novel anti-
inflammatory oral therapies such as selective
phosphodiesterase inhibitors or long-term antibiotic therapy
in exacerbation prevention needs to be determined.
Whilst pharmacotherapies clearly have a role to play in
preventing exacerbations, there remains a need for additional
physical therapies in reducing the impact of these events on
patients and carers. Pulmonary rehabilitation is a multi-
disciplinary strategy to optimize symptom control, physical
capacity, and health-related quality of life and to limit the
psychological impact of disease and to prevent
complications and exacerbations (Pauwels et al 2001). It
has become established as a useful strategy for improving
exercise tolerance and functional ability in subjects with
COPD, with associated benefits on health status (Goldstein
et al 1994; Ries et al 1995; Troosters et al 2000). Despite
these benefits, results from trials that examined effects on
exacerbation frequency are at best mixed. One such study,
in a large group of patients with mixed respiratory disease,
largely COPD, found that a 6-week course of pulmonary
rehabilitation had no effect on numbers of hospital
admissions but did considerably reduce the length of stay
and requirement for home visits by general practitioners
(Griffiths 2000). It is perhaps surprising when poor
functional status is a risk factor for hospital admission
(Garcia-Aymerich et al 2003) that methods to improve
functional status have not affected hospital admissions.
A study of a new approach to pulmonary rehabilitation
investigated the benefit of initiating rehabilitation
immediately after discharge following admission for an
acute exacerbation. Despite few patients, with this approach
the treatment group had fewer visits to accident and
emergency, with trends towards fewer hospital admissions
and bed days in the 3-month follow up period (Man et alInternational Journal of COPD 2006:1(3) 338
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2004). Clearly, pulmonary rehabilitation can play a major
role in the management of COPD and in improving
exacerbation outcome; however, further studies are required
to determine the optimal timing of this intervention with
respect to improving exacerbation outcomes and preventing
recurrence.
Health care delivery and
exacerbation outcomes
There is considerable evidence that currently available
therapies such as antibiotics (Anthonisen et al 1987), and
oral corticosteroids (Thompson et al 1996; Davies et al
1999; Niewoehner et al 1999; Aaron et al 2003) improve
exacerbation outcomes; however, debate continues
whether these therapies are indicated across the spectrum
of disease severity and heterogeneity of exacerbation
phenotypes. If we accept that the administration of
additional therapies at exacerbation benefits recovery
then in the absence of established self-management
protocols the patient must consult their physician before
therapy can be administered and the benefits obtained.
Using a symptom-based definition of exacerbation with
daily data collection, it has been demonstrated that a
significant proportion of exacerbations are not reported
to a physician for therapy (Wilkinson et al 2004).
Importantly these “unreported exacerbations” were
associated with worse health status and patients with
persistently poor reporting behavior were those most
likely to be hospitalized for emergency management of
exacerbations (Wilkinson et al 2004).
 The causes of poor health utilization behavior are
likely to be complex, but may be affected by poor patient
understanding of their condition (Rennard et al 2002),
high levels of anxiety and depression common in patients
with COPD (Okubadejo et al 1996), social isolation and
poor access to health care. Even if health care access is
optimized this inadequate exacerbation reporting
behavior persists (Wilkinson et al 2004), suggesting that
patients’ perception of their condition and attitudes to
therapy may be paramount in modulating health-seeking
behavior at exacerbation.
When patients do seek therapy for exacerbations they
often delay presentation for several days after the onset
of symptoms (Wilkinson et al 2004). Those individuals
who present for therapy early have better outcomes than
those who delay presentation after the onset of symptoms
(Wilkinson et al 2004). This suggests that improving
patient reporting behavior will improve the beneficial
effects that standard exacerbation therapy has on
outcomes. Interventional studies using an early treatment
intervention are required.
One model of therapy that may improve patients’
symptom perception and reduce time taken to initiate
therapy is self-management. Those studies that have been
undertaken suggest that self-management plans improve
health related quality of life (Howland et al 1986;
Littlejohns et al 1991; Bourbeau et al 2003) and may
reduce hospitalization (Bourbeau et al 2003). However,
such studies have, quite appropriately, used models of
self-management that have affected all aspects of patients’
disease; both stable and exacerbation, and have thus
shown improvements in indicators of overall health such
as quality of life measures. Whether self-management of
exacerbations of COPD is appropriate, safe, and
efficacious requires further study.
The burden associated with hospital admission for
COPD exacerbations is extremely high: in the UK acute
exacerbations account for 10% of all acute medical
admissions (Kendrick et al 1994) and age-adjusted
admission rates have risen greatly in recent years (Guest
1999). Alternatives to traditional inpatient care have been
sought to reduce this burden on secondary care. A number
of intervention studies using a “hospital at home” service
have now been evaluated. These innovations aim to
provide a complete and effective care package in the
patients’ home as an alternative to admission or as a way
of facilitating early discharge from hospital. A systematic
review of the key studies, involving 754 patients in 7
studies, concluded that these schemes were as safe and
as effective as current in-patient care (Ram et al 2004).
Accepting the inherent flaws of such analyses; differing
inclusion and exclusion criteria, and variation in models
of care used and primary outcomes measured, the data
would suggest the safety of such schemes is at least
equivalent to inpatient care. However, audit of UK in-
patient exacerbation care reveals that the level of in-
patient care given is often suboptimal (Roberts 2001),
and therefore objective comparative standards for new
models of care should be established for future studies.
It is important that while these studies are performed to
determine which patients and which components of care
should be included in hospital-at-home schemes, the
overall delivery of care for these events begins to
approach the standards set out in current guidelines more
closely (NICE 2004).International Journal of COPD 2006:1(3) 339
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Preventing hospital admissions and
re-admissions
The majority of health care costs associated with
exacerbations are incurred by the management of severe
events requiring hospitalization (Oostenbrink et al 2004).
Therefore it is important that the modifiable risk factors
associated with hospital admission are identified and where
possible addressed. The EFRAM study performed in Spain
has investigated the common features associated with
hospitalization for exacerbation. The authors identified high
incidence of a number of modifiable risk factors in a
population of patients admitted for management of acute
exacerbations. These included active smoking, low rates of
involvement in rehabilitation programmes, inappropriate use
of oxygen therapy, and poor inhaler technique (Garcia-
Aymerich et al 2000). However, a further analysis of case
control data revealed that only previous frequent admissions,
disease severity as determined by the FEV1, active smoking,
and under-prescription of long-term oxygen therapy were
associated with increased risk of hospitalization (Garcia-
Aymerich et al 2000). These data suggest scope for
interventions to prevent admission, with this evidence
underlining the role of established measures such as smoking
cessation and adequate provision of oxygen therapy.
It is becoming increasingly recognized that hospital
admission for a COPD exacerbation is not only an important,
expensive, and potentially preventable event, but may also
signify that a particular individual is at risk of further
exacerbations, hospitalization, and early mortality. A follow
up to the EFRAM study examined risk factors for re-
admission to hospital after in-patient management of an
index exacerbation. During the 1.1-year follow up more than
60% of subjects were re-admitted and 29% died (Garcia-
Aymerich et al 2003). In addition to the risk factors identified
in the previous studies (Garcia-Aymerich et al 2000, 2001)
the finding that high levels of “usual physical activity” were
associated with reduced risk of re-admission suggests a
potentially beneficial effect of pulmonary rehabilitation in
preventing hospitalization as discussed previously, with the
timing of rehabilitation early in the recovery phase important
in preventing re-admission (Man 2004). A similar model of
early rehabilitation as an adjunct to a hospital-at-home
scheme suggests a benefit in preventing re-admission by
improving functional status early in the recovery phase of
an exacerbation (Murphy et al 2005). As highlighted
previously, patients requiring acute non-invasive ventilation
do very badly following discharge: approximately 80% were
re-admitted and half died within a year (Chu et al 2004).
While there is now an established role for acute non-invasive
ventilation in the management of exacerbations (Brochard
et al 1995; NICE 2004), the role of long-term non-invasive
ventilation (NIV) in improving outcomes in these severe
patients is not fully proven. While a definitive study has
not been performed, current data would suggest that long-
term NIV in stable COPD may reduce hospital admissions,
length of stay, and importantly prove to be cost-effective
compared with usual care (Tuggey et al 2003).
Health care utilization at the time of an exacerbation
can also provide an opportunity to address the prevalent
psychological as well as physical morbidity associated with
COPD (Howland et al 1986). Recent guidelines highlight
the importance of addressing these issues in the management
of patients with COPD; however, there is little evidence to
guide interventions or to determine their benefit (NICE
2004).
Optimizing therapy for acute
exacerbations
There is now an expanding evidence base to demonstrate a
beneficial effect on exacerbation outcomes for a number of
existing therapies. There is for example established evidence
for the use of oral corticosteroids in the management of
exacerbations: they have been shown to reduce the length
of hospital stay, and they can accelerate the rate of
improvement in lung function (Thompson et al 1996; Davies
et al 1999; Niewoehner et al 1999; Aaron et al 2003).
However, the size of effect in randomized controlled trials
is relatively small. There is no observable additional benefit
from administration of longer courses (Niewoehner et al
1999) and current guidelines recommend a 7- to 10-day
regime for hospital inpatients. The data available on the role
of oral corticosteroids in the treatment of milder
exacerbations, for example those seen in a primary care
setting, are less substantial.
The role of antibiotics in the management of
exacerbations remains controversial. Whilst analysis of
studies examining the effect of antibiotics on exacerbations
as a whole suggest a benefit on outcomes (Saint et al 1995),
the seminal study on this topic found an outcome advantage
in only treating patients with oral antibiotics who presented
with symptoms of sputum volume, purulence, and dyspnea
(Anthonisen et al 1987). This suggests that clinical
symptoms may predict which patients will benefit from
antibiotic therapy. This is confirmed by indirect evidenceInternational Journal of COPD 2006:1(3) 340
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that sputum purulent exacerbations are more likely to
demonstrate a response to antibiotics, as they have a higher
rate of isolation of bacterial airway pathogens (Stockley et
al 2000). It would seem that targeting antibiotic use to more
severe exacerbations associated with sputum purulence may
seem an appropriate way of maximizing benefit while
limiting their over-prescription.
A recent study examined the benefits of intravenous
aminophylline in the acute management of exacerbations
in in-patients’ therapy and found no benefit in addition to
standard therapy (Duffy et al 2005). Despite this evidence
and the risks of serious side-effects, use of parental
methylxanthines in this context remains widespread..
 Clinicians are aware of the potential benefits and
complications associated with the use of supplemental
oxygen for patients with severe disease. The guidelines on
the use of supplemental oxygen are explicit although the
evidence base is weak. It is important that patients at risk of
developing hypercapnic respiratory failure in response to
supplemental oxygen are identified early and appropriate
assessment of arterial blood gases is necessary in doing this
(Plant et al 2000). The use of NIV for the management of
hypercapnic exacerbations can greatly improve outcomes
for the patients with severe COPD (Plant et al 2000) and
there are well-established parameters encompassed in the
guidelines covering appropriate indications for this
treatment.
Despite guidelines on their administration, delivery of
treatment in the acute stage may be sub-optimal, and
evidence that specialist respiratory care is associated with
better outcomes than non-specialist care suggests that
appropriate use of available treatments is an important
process in improving outcomes (Roberts et al 2003). Clearly
there is a role for expanding specialist care, multidisciplinary
teamwork, and evidence-based care pathways in the
management of exacerbations.
Conclusion
Despite a wealth of new evidence from basic science and
clinical research to improve our understanding of COPD
exacerbations, coupled with tangible improvements in health
service provision, exacerbations remain an important cause
of morbidity and mortality. The natural history and
consequences of these events, particularly in patients with
more severe disease, has only recently been recognized.
However, there are at the clinician’s disposal a number of
existing therapies which, if used effectively, can improve
the poor outcome of COPD exacerbations. While we await
the development of novel and more efficacious
pharmacological therapies, the great should not become the
enemy of the good. By improving the delivery of care,
identifying and targeting high-risk patients and adopting a
multi-disciplinary approach we can improve the outlook for
patients with this prevalent and disabling disease.
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